Sanofi (NASDAQ:SNY - Free Report) - Analysts at Zacks Research boosted their Q1 2027 earnings per share (EPS) estimates for shares of Sanofi in a research report issued on Tuesday, July 8th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $1.16 per share for the quarter, up from their previous estimate of $1.15. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi's Q2 2027 earnings at $1.29 EPS and FY2027 earnings at $5.17 EPS.
A number of other analysts also recently commented on SNY. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $61.50.
Get Our Latest Stock Analysis on Sanofi
Sanofi Stock Performance
Sanofi stock traded down $0.73 during trading hours on Thursday, hitting $48.61. 1,207,445 shares of the stock traded hands, compared to its average volume of 2,330,352. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The stock has a market capitalization of $119.21 billion, a price-to-earnings ratio of 17.36, a P/E/G ratio of 1.12 and a beta of 0.48. The firm's 50 day moving average price is $50.05 and its 200-day moving average price is $52.08.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company's quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.78 EPS.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Cardinal Capital Management raised its stake in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares in the last quarter. Gradient Investments LLC raised its stake in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after acquiring an additional 200 shares in the last quarter. Providence Capital Advisors LLC raised its stake in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after acquiring an additional 201 shares in the last quarter. Perigon Wealth Management LLC raised its stake in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after acquiring an additional 201 shares in the last quarter. Finally, Capital Analysts LLC raised its stake in shares of Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock valued at $92,000 after acquiring an additional 204 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Increases Dividend
The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a $2.0369 dividend. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.
About Sanofi
(
Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
